SEQUANA MEDICAL NV (SEQUA.BR) Stock Price, Forecast & Analysis
Europe - Euronext Brussels - EBR:SEQUA - BE0974340722 - Common Stock
SEQUA.BR Key Statistics, Chart & Performance
The current stock price of SEQUA.BR is 0.653 EUR. In the past month the price increased by 4.48%. In the past year, price decreased by -83.13%.
SEQUA.BR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1MDT.MI | MEDTRONIC PLC | 17.59 | 107.77B | ||
| 2M6.DE | MEDTRONIC PLC | 17.36 | 106.36B | ||
| SHL.DE | SIEMENS HEALTHINEERS AG | 18.62 | 50.20B | ||
| PHI1.DE | KONINKLIJKE PHILIPS NV | 15.41 | 21.95B | ||
| 1PHIA.MI | KONINKLIJKE PHILIPS NV | 15.38 | 21.92B | ||
| PHIA.AS | KONINKLIJKE PHILIPS NV | 15.36 | 21.90B | ||
| BIM.PA | BIOMERIEUX | 28.5 | 13.02B | ||
| OBCK.DE | OTTOBOCK SE & CO KGAA | 137.87 | 4.15B | ||
| DIA.MI | DIASORIN SPA | 20.13 | 3.73B | ||
| AFX.DE | CARL ZEISS MEDITEC AG - BR | 25.03 | 3.60B | ||
| DRW3.DE | DRAEGERWERK AG - PREF | 10.6 | 1.28B | ||
| ELN.MI | EL.EN. SPA | 21.7 | 1.12B |
Related stock screener links
About SEQUA.BR
Company Profile
Sequana Medical NV is a commercial stage medical device company, which engages in the design, development, manufacture, and commercialization of medical device. The company is headquartered in Ghent, Oost-Vlaanderen and currently employs 48 full-time employees. The company went IPO on 2019-02-11. The firm focuses mainly on the development of treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders. Sequana Medical NV provides alfapump, which is an implantable, programmable, wireless-charged and battery-powered system that is CE-marking for the management of refractory ascites due to liver cirrhosis and malignant ascites. Over 650 alfapump systems have been implanted. Apart from the Alfapump, the Company also aims to develop a direct sodium removal (DSR) therapy, which is a propriety approach to the treatment of volume overload in heart failure.
Company Info
SEQUANA MEDICAL NV
Kortrijksesteenweg 1112, Sint-Denijs-Westrem
Ghent OOST-VLAANDEREN BE
Employees: 48
Phone: 3292928065.0
SEQUANA MEDICAL NV / SEQUA.BR FAQ
What does SEQUA do?
Sequana Medical NV is a commercial stage medical device company, which engages in the design, development, manufacture, and commercialization of medical device. The company is headquartered in Ghent, Oost-Vlaanderen and currently employs 48 full-time employees. The company went IPO on 2019-02-11. The firm focuses mainly on the development of treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders. Sequana Medical NV provides alfapump, which is an implantable, programmable, wireless-charged and battery-powered system that is CE-marking for the management of refractory ascites due to liver cirrhosis and malignant ascites. Over 650 alfapump systems have been implanted. Apart from the Alfapump, the Company also aims to develop a direct sodium removal (DSR) therapy, which is a propriety approach to the treatment of volume overload in heart failure.
What is the stock price of SEQUANA MEDICAL NV today?
The current stock price of SEQUA.BR is 0.653 EUR. The price decreased by -4.67% in the last trading session.
Does SEQUANA MEDICAL NV pay dividends?
SEQUA.BR does not pay a dividend.
What is the ChartMill technical and fundamental rating of SEQUA stock?
SEQUA.BR has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
How is the market expecting SEQUA stock to perform?
10 analysts have analysed SEQUA.BR and the average price target is 2.79 EUR. This implies a price increase of 326.95% is expected in the next year compared to the current price of 0.653.
Can you provide the market cap for SEQUANA MEDICAL NV?
SEQUANA MEDICAL NV (SEQUA.BR) has a market capitalization of 44.46M EUR. This makes SEQUA.BR a Nano Cap stock.
SEQUA.BR Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to SEQUA.BR. When comparing the yearly performance of all stocks, SEQUA.BR is a bad performer in the overall market: 97.71% of all stocks are doing better.
SEQUA.BR Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to SEQUA.BR. SEQUA.BR may be in some trouble as it scores bad on both profitability and health.
SEQUA.BR Financial Highlights
Over the last trailing twelve months SEQUA.BR reported a non-GAAP Earnings per Share(EPS) of -1.24. The EPS decreased by -31.91% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -346.67% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
SEQUA.BR Forecast & Estimates
10 analysts have analysed SEQUA.BR and the average price target is 2.79 EUR. This implies a price increase of 326.95% is expected in the next year compared to the current price of 0.653.
For the next year, analysts expect an EPS growth of 81.63% and a revenue growth 782.35% for SEQUA.BR